
|Articles|October 1, 2003
Vision outcomes create optimistic expectation for spectacle independence
Author(s)Cheryl Guttman
Editor's Note: The CrystaLens was recommended for approval by the FDA's Ophthalmic Devices Advisory Panel in late May. The lens may be commercially available later this year or early 2004. Dr. Doane's presentation was given at the annual meeting of the American Society of Cataract and Refractive Surgery prior to the recommendation.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Avisi Technologies treats first patient in SAPPHIRE trial for glaucoma
2
FDA approves Amneal Pharmaceuticals' cyclosporine ophthalmic emulsion 0.05%
3
Lotus submits NDA in South Korea for LENZ’s presbyopia treatment VIZZ
4
Belite Bio releases topline results from phase 3 DRAGON trial of Tinlarebant for STGD1
5















































.png)


